Functional outcomes, treatment satisfaction, decisional regret, and the impact of institutional factors after robotic vs. retropubic radical prostatectomy: a 5 year follow-up of the HAROW study

Functional outcomes, treatment satisfaction, decisional regret, and the impact of institutional factors after robotic vs. retropubic radical prostatectomy: a 5 year follow-up of the HAROW study - HAROW-RPE-FU

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011501

Enrollment

1260

Registered

2017-01-10

Start date

2017-01-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Patients after robotic radical prostatectomy are provided with a questionnaire. This questionnaire includes clinical data, the Control Preferences Scale (Degner & Sloan 1992), the Decision Re

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Patients must have taken part in the HAROW study and have consented to long-term follow-up. 2) Patients must have undergone either retropubic or robotic-assisted radical prostatectomy. 3) Patient data must have been sufficient for analysis in the HAROW study. Inclusion criteria from the HAROW study: 4) Newly diagnosed patients with a prostate cancer that is limited to the prostate gland (max. tumor staging T2c) 5) Patients without known metastases (N0, M0)

Exclusion criteria

Exclusion criteria: 1) Recurrence of prostate cancer 2) Tumor staging T3 or greater

Design outcomes

Secondary

Measure	Time frame
Secondary endpoints are decisional regret (Decision regret scale), the retrospective judgment of the decision-making process (Degner scale) and quality of life (EORTC-QOL-30).	—

Primary

Measure	Time frame
Primary endpoint is to compare long-term functional outcome (EPIC-26).	—

Countries

Germany

Contacts

Public ContactElke Hempel

SMG Forschungsgesellschaft mbH

Elke.Hempel@smgf.de+49 30 284450-01

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026